Home › Research › Biomarkers
Potential utility of plasma pTau217 for assessing amyloid and tau biomarker profiles
Shin D, Jang H, Yoo H, Kim K, Zetterberg H, Blennow K, Gonzalez-Ortiz F, Ashton NJ et al.. European journal of nuclear medicine and molecular imaging, 2025-08-06
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Purpose Plasma phosphorylated tau 217 (pTau217) is a promising biomarker for Alzheimer's disease, reflecting both amyloid β (Aβ) and tau positron emission tomography (PET) results. While its diagnostic role is actively being investigated, this study aims to expand its application to staging disease progression and predicting cognitive decline. Methods A total of 2,919 participants, primarily diagnosed as Alzheimer's clinical syndrome, were recruited. Plasma pTau217 was measured using the ALZpath assay, and its diagnostic accuracy for binary Aβ/tau (A/T) biomarker profiles and Aβ and tau PET staging was assessed using area under the curve (AUC). Longitudinal Mini-Mental State Examination (MMSE) changes according to plasma pTau217-based staging were analyzed. Results Plasma pTau217 accurately predicted binary Aβ (AUC 0.96) and tau (AUC 0.90) PET positivity. Both the Aβ-positive/tau-positive (A ptau +/T ptau +) and Aβ-positive/tau-negative (A ptau +/T ptau -) groups, defined using plasma pTau217 cutoffs, showed significantly worse MMSE trajectories compared to the Aβ-negative/tau-negative (A ptau -/T ptau -) group (for A ptau +/T ptau + vs. A ptau -/T ptau -, β = -1.061 ± 0.055; for A ptau +/T ptau - vs. A ptau -/T ptau -, β = -0.322 ± 0.070, all adjusted P < 0.001). However, its performance was less effective for Aβ and tau PET staging, particularly for medial temporal tau PET stage (AUC 0.71). Nevertheless, plasma pTau217-based staging distinguished longitudinal MMSE deterioration (all adjusted P < 0.001). Conclusion Plasma pTau217 is effective for predicting A/T biomarker profile and cognitive decline, though further study is needed to better explain its association with Aβ and tau PET staging. Clinical trial number Not applicable.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Shin, D., Jang, H., Yoo, H., Kim, K., Zetterberg, H., Blennow, K., et al. (2025). Potential utility of plasma pTau217 for assessing amyloid and tau biomarker profiles. European journal of nuclear medicine and molecular imaging. https://doi.org/10.1007/s00259-025-07457-y
Vancouver
Shin D, Jang H, Yoo H, Kim K, Zetterberg H, Blennow K, et al. Potential utility of plasma pTau217 for assessing amyloid and tau biomarker profiles. European journal of nuclear medicine and molecular imaging. 2025. doi:10.1007/s00259-025-07457-y. PMID: 40768095.
BibTeX
@article{shin2025-40768095,
author = {Shin, D. and Jang, H. and Yoo, H. and Kim, K. and Zetterberg, H. and Blennow, K. and Gonzalez-Ortiz, F. and Ashton, N. J. and others},
title = {{Potential utility of plasma pTau217 for assessing amyloid and tau biomarker profiles}},
journal = {European journal of nuclear medicine and molecular imaging},
year = {2025},
doi = {10.1007/s00259-025-07457-y},
pmid = {40768095},
url = {https://doi.org/10.1007/s00259-025-07457-y}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Purpose Plasma phosphorylated tau 217 (pTau217) is a promising biomarker for Alzheimer's disease, reflecting both amyloid β (Aβ) and tau positron emission tomography (PET) results.
- Results Plasma pTau217 accurately predicted binary Aβ (AUC 0.96) and tau (AUC 0.90) PET positivity.
- Both the Aβ-positive/tau-positive (A ptau +/T ptau +) and Aβ-positive/tau-negative (A ptau +/T ptau -) groups, defined using plasma pTau217 cutoffs, showed significantly worse MMSE trajectories compared to the Aβ-negative/tau-negative (A ptau -/T ptau -) group (for A ptau +/T ptau + vs.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designlongitudinal study
- Participants2,919
- Effect sizeAUC 0.96; AUC 0.90; AUC 0.71
- Evidence strengthModerate
How this study scored 76/100
Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 44 of the 58 points we could judge it on, which is 76 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (European journal of nuclear medicine and molecular imaging) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 7 / 12 | A longitudinal study following the same people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 3 / 4 | 2,919 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40768095) |
| Free to read | 2 / 2 | Free to read |
| Points | 44 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 44 of the 58 points we could judge it on is 76 out of 100. |
| Total | 76 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also tagged “plasma-ptau217”
5 studies in the library carry the topic tag “plasma-ptau217”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 5 tagged studies.